Results 1 to 10 of about 38,962 (211)

Acquired factor VII deficiency causing severe bleeding disorder secondary to AL amyloidosis of the liver

Hematology Reports, 2018
A 52 year-old male presented with neck pain after undergoing thyroidectomy for a goiter three weeks prior which was complicated by a neck hematoma requiring evacuation.
Anthony L. Nguyen, Muhammad Kamal, Ravi Raghavan, Gayathri Nagaraj   +3 more
doaj   +1 more source

Modified Protocol to Enable the Study of Hemorrhage and Hematoma in a Traumatic Brain Injury Mouse Model

Frontiers in Neurology, 2021
To date, many studies using the controlled cortical impact (CCI) mouse model of traumatic brain injury (TBI) have presented results without presenting the pathophysiology of the injury-core itself or the temporal features of hemorrhage (Hrr).
Hyejin Joo, Jinhyun Bae, Jae-Woo Park, Beom-Joon Lee, Byoung Dae Lee, Youngmin Bu   +5 more
doaj   +1 more source

HEMOPHILIA INHIBITOR PATIENTS: THE USE OF RECOMBINANT FACTOR VIIa

Zdravniški Vestnik, 2004
Background. Recombinant factor VIIa can induce hemostasis and controls bleeding in surgery in hemophilia inhibitor patients and in other hemostatic disorders, e.g.
Dušan Andoljšek, Samo Zver
doaj  

Factor VIIa administration in traumatic brain injury: an AAST-MITC propensity score analysis. [PDF]

, 2018
Background:Recombinant factor VIIa (rFVIIa) has been used off-label as an adjunct in the reversal of warfarin therapy and management of hemorrhage after trauma. Only a handful of these reports are rigorous studies, from which results regarding safety and
Coimbra, Raul, Jurkovich, Gregory J, Lombardo, Sarah, Millar, D, Nirula, Ram   +4 more
core   +2 more sources

Activated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: it is mostly ineffective, is expensive, and may rarely cause serious adverse events [PDF]

, 2014
Activated Recombinant Factor VIIa Does Not Improve Mortality in Variceal Bleeding. Bendtsen F, D’Amico G, Rusch E, de Franchis R, Anderson PK, Lebrec D, et al. Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: An individual patient
Chalasani, Naga, Sozio, Margaret S.
core   +1 more source

Acquired factor VII inhibitor associated with primary central nervous system Lymphoma: A case report

eJHaem, 2022
Paraneoplastic coagulopathies are uncommon in patients with lymphoma. We report the first case of an acquired coagulopathy in a patient with isolated primary central nervous system lymphoma (PCNSL) demonstrating large‐cell histology.
Vanshika Goyal, Giselle Salmasi, Andrew D. Leavitt, James L. Rubenstein, Rahul Banerjee   +4 more
doaj   +1 more source

Failure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding

BMC Infectious Diseases, 2007
Background This report discusses a case of unsuccessful treatment with recombinant factor VIIa (rFVIIa) in off-label use. The need for international guidelines concerning the off-label use of rFVIIa is outlined as well as the need for methods to control ...
Tsakiris Dimitrios A, Weisser Maja, Conen Anna, Siegemund Martin   +3 more
doaj   +1 more source

Supersymmetry and Membrane Interactions in M(atrix) Theory

, 1997
We calculate the potential between various configurations of membranes and gravitons in M(atrix) theory. The computed potentials agree with the short distance potentials between corresponding 2-branes and 0-brane configurations in Type IIA string theory,
Abouelsaood, Aharony, Bachas, Bachas, Banks, Berkooz, Breckenridge, Dai, Danielson, de Wit, de Wit, Douglas, Ganor, Gilad Lifschytz, Green, Green, Hull, Kabat, Leigh, Lifschytz, Lifschytz, Periwal, Polchinski, Russo, Samir D. Mathur, Taylor, Witten, Witten   +27 more
core   +1 more source

A Comparison between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients with Congenital Factor VII Deficiency [PDF]

, 2015
In order to establish the efficacy and biosimilar nature of AryoSeven to NovoSeven in the treatment of congenital factor VII (FVII) deficiency, patients received either agent at 30 1/4g/kg, intravenously per week for 4 weeks, in a randomized fashion. The
Abolghasemi, H., Ahmadinejad, M., Baghaeipour, M.R., Dehdezi, B.K., Eshghi, P., Faranoush, M., Fayazfar, R., Heshmat, R., Hoorfar, H., Kamyar, K., Karimi, M., Khoeiny, B., Managhchi, M., Mehrvar, A., Mirbehbahani, N.B., Naderi, M., Toogeh, G.   +16 more
core  

Non-local Operations: Purification, storage, compression, tomography, and probabilistic implementation

, 2000
We provide several applications of a previously introduced isomorphism between physical operations acting on two systems and entangled states [1]. We show: (i) how to implement (weakly) non-local two qubit unitary operations with a small amount of ...
A. Jamiolkowski, A. Rauschenbeutel, A. Thapliyal, B. Kraus, B. Schumacher, C. A. Sackett, C. H. Bennett, C. H. Bennett, C. H. Bennett, C. H. Bennett, C. H. Bennett, D. Boschi, D. Bouwmeester, D. Bouwmeester, D. Bruss, D. Bruss, D. Deutsch, D. P. DiVincenzo, G. Giedke, H. Weinfurter, H.-J. Briegel, I. L. Chuang, J. Eisert, J. F. Poyatos, J. I. Cirac, J. I. Cirac, J. I. Cirac, J. I. Cirac, J. Kempe, J.- W. Pan, K. Mattle, K. Vogel, M. A. Nielsen, M. Horodecki, N. Gisin, N. Lütkenhaus, P. Zanardi, P. Zanardi, P. Zanardi, R. F. Werner, R. Werner, S. L. Braunstein, V. Bužek, V. Bužek, W. Dür, W. Dür, W. Dür, W. Dür, W. Dür, W. Dür, W. Dür   +50 more
core   +1 more source